BOTULINUM TOXIN TYPE B

ApprovedSmall molecule

Eisai

BOTULINUM TOXIN TYPE B is one of 104 small molecule programs targeting Cervical Dystonia. It is currently in Approved.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaActive, not recruiting

TorticollisActive, not recruiting

DystoniaActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Systemic SclerosisActive, not recruiting

Cervical DystoniaApproved

Active, not recruiting

TorticollisPhase 2

Active, not recruiting

DystoniaApproved

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 2/Phase 3

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

220 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

2 2

Radicava

Shionogi

Phase 3

2 3

Simdax

Orion Corporation, Orion Pharma

Phase 3

1 4

BOTULINUM TOXIN TYPE B

Eisai

Approved

1 5

Ultomiris

Robitussin

Lithobid

SSolvay Pharmaceuticals

Phase 3

3 8

Minocin

TTriax

Phase 3

2 9

Sodium Valproate

AstraZeneca

Phase 3

1 10

Namenda

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Torticollis1 trial

Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis

Completed· Eisai logo

Eisai·Phase 2·NCT00165776·133 enrolled

Dystonia1 trial

Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia

Completed·—·Phase 4·NCT00208091·16 enrolled

Systemic Sclerosis1 trial

Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis

Completed·GGunma University·Phase 2·NCT03007004·10 enrolled

Parkinson's Disease1 trial

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

Completed·SSolstice Neurosciences·Phase 2·NCT00515437·54 enrolled

Amyotrophic Lateral Sclerosis1 trial

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2/3·NCT00125203·20 enrolled

2 more indications

Cervical Dystonia1 trial

An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia

Completed·SSolstice Neurosciences·Phase 4·NCT00702754·502 enrolled

Extremity1 trial

"DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?"

Completed·SStanford University·Phase 1/2·NCT00238641·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BOTULINUM TOXIN TYPE B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BOTULINUM TOXIN TYPE B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BOTULINUM TOXIN TYPE B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eisai

BOTULINUM TOXIN TYPE B

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Torticollis1 trial

Dystonia1 trial

Systemic Sclerosis1 trial

Parkinson's Disease1 trial

Amyotrophic Lateral Sclerosis1 trial

Cervical Dystonia1 trial

Extremity1 trial

References

Drug Info

Quick Facts

Related News